Beyond Psilocybin: Reviewing the Therapeutic Potential of Other Serotonergic Psychedelics in Mental and Substance Use Disorders

Wong, Stanley; Yu, An Yi; Fabiano, Nicholas; Finkelstein, Ofer; Pasricha, Aryan; Jones, Brett D.M.; Rosenblat, Joshua D.; Blumberger, Daniel M.; Mulsant, Benoit H.; Husain, M. Ishrat

doi:10.1080/02791072.2023.2251133

Journal of Psychoactive Drugs

2023

DOI: 10.1080/02791072.2023.2251133

|View full text |Cite

Beyond Psilocybin: Reviewing the Therapeutic Potential of Other Serotonergic Psychedelics in Mental and Substance Use Disorders

Stanley Wong,

An Yi Yu,

Nicholas Fabiano

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 113 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Psychedelics: A review of their effects on recalled aversive memories and fear/anxiety expression in rodents

Werle,

Bertoglio

2024

Neuroscience & Biobehavioral Reviews

View full text Add to dashboard Cite

Psychedelics: A review of their effects on recalled aversive memories and fear/anxiety expression in rodents

Werle,

Bertoglio

2024

Neuroscience & Biobehavioral Reviews

View full text Add to dashboard Cite

Small-Molecule Heterocyclic Compounds: Gq-Biased Agonists for the 5-HT2A Receptor in Neuropsychiatric Treatment

Kargbo

2023

ACS Med. Chem. Lett.

View full text Add to dashboard Cite

Addressing the significant challenges of treating depression, anxiety, and substance abuse, this Patent Highlight explores the development of innovative small-molecule heterocyclic compounds as Gq-biased agonists of the 5-HT2A receptor. Unlike traditional treatments, these compounds selectively activate 5-HT2A-mediated Gq signaling, excluding related receptors like 5-HT2B and 5-HT2C. This selectivity suggests a more targeted and efficient therapeutic approach. The discovery of these compounds could herald a new era in neuropsychiatric treatment, promising safer, faster, and more effective interventions. Further research will illuminate their potential and applicability in clinical settings.

show abstract

Personal Psychedelic Experience as a Training Qualification for Facilitators: A Thematic Analysis of Qualitative Interviews with Psilocybin Experts

Wilson-Poe,

Hoffman,

Pertl

et al. 2024

Journal of Psychoactive Drugs

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Beyond Psilocybin: Reviewing the Therapeutic Potential of Other Serotonergic Psychedelics in Mental and Substance Use Disorders

Cited by 3 publications

References 113 publications

Psychedelics: A review of their effects on recalled aversive memories and fear/anxiety expression in rodents

Psychedelics: A review of their effects on recalled aversive memories and fear/anxiety expression in rodents

Small-Molecule Heterocyclic Compounds: Gq-Biased Agonists for the 5-HT2A Receptor in Neuropsychiatric Treatment

Personal Psychedelic Experience as a Training Qualification for Facilitators: A Thematic Analysis of Qualitative Interviews with Psilocybin Experts

Contact Info

Product

Resources

About